Esperion's LDL-C hangover

Why Esperion fell again on FDA's lack of committal to LDL-C

The fall of Esperion Therapeutics Inc. (NASDAQ:ESPR) continued last month as FDA's refusal to commit to LDL-C lowering as an approvable surrogate endpoint for the company's statin alternative has seen the biotech lose 90% of its value in the past year.

On

Read the full 443 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE